Background-Pulmonary nodules (PNs) are often detected incidentally during coronary computed tomographic (CT) angiography, which is increasingly being used to evaluate patients with chest pain symptoms. However, the efficiency of following up on incidentally detected PN is unknown. Methods and Results-We determined demographic and clinical characteristics of stable symptomatic patients referred for coronary CT angiography in whom incidentally detected PNs warranted follow-up. A validated lung cancer simulation model was populated with data from these patients, and clinical and economic consequences of follow-up per Fleischner guidelines versus no follow-up were simulated. Of the 3665 patients referred for coronary CT angiography, 591 (16%) had PNs requiring follow-up. The mean age of patients with PNs was 59±10 years; 66% were male; 67% had ever smoked; and 21% had obstructive coronary artery disease. The projected overall lung cancer incidence was 5.8% in these patients, but the majority died of coronary artery disease (38%) and other causes (57%). Follow-up of PNs was associated with a 4.6% relative reduction in cumulative lung cancer mortality (absolute mortality: follow-up, 4.33% versus non-follow-up, 4.54%), more downstream testing (follow-up, 2.34 CTs per patient versus non-follow-up, 1.01 CTs per patient), and an average increase in quality-adjusted life of 7 days. Costs per quality-adjusted life-year gained were $154 700 to follow up the entire cohort and $129 800 per quality-adjusted life-year when only smokers were included. Conclusions-Follow-up of PNs incidentally detected in patients undergoing coronary CT angiography for chest pain evaluation is associated with a small reduction in lung cancer mortality. However, significant downstream testing contributes to limited efficiency, as demonstrated by a high cost per quality-adjusted life-year, especially in nonsmokers. (Circulation. 2014;130:668-675.)
C oronary computed tomographic (CT) angiography (CCTA) is a viable alternative to functional testing to evaluate patients presenting with chest pain.
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CCTA data acquisition includes coverage of parts of the lungs, mediastinum, bones, and upper abdomen. Typically, raw CT data are reconstructed so that these additional structures can be evaluated for the presence of noncardiac incidental findings, which are relatively common (prevalence, 23%-48%) in patients undergoing CCTA. The vast majority of incidental findings (80%) are solid pulmonary nodules (PNs). [4] [5] [6] [7] [8] With the increasing clinical use of CCTA, referring physicians are more frequently challenged by the recommendation to follow up on PNs despite negative coronary artery disease (CAD) assessment. Data on the prognostic benefits, costs, and impacts on quality of life of reporting incidental PNs are needed to inform a policy of reporting incidental PNs because this has important implications beyond CCTA. 9, 10 Hence, we determined the characteristics of a referral cohort of patients with PNs incidentally detected during CCTA and then used a validated lung cancer simulation model to compare the resource use, costs, mortality, and cost-effectiveness of a strategy that performs follow-up testing and treatment of incidental PNs relative to no follow-up.
Methods
Protected Health Information
The protocol for the use of human subject data for this analysis was approved by the Institutional Review Board at Massachusetts General Hospital.
Patient Population
Medical records of patients who were clinically referred for CCTA for the evaluation of CAD at our tertiary academic medical center between January 1, 2005, and December 31, 2008, were reviewed to identify patients in whom PNs were incidentally detected during CCTA. Demographic data for these patients, including age, sex, current smoking status, history of malignancy, history of CAD (coronary artery bypass grafting, surgery, or coronary artery stent placement), and chest pain symptoms, were recorded. Because of a lack of detailed smoking history in medical records, we used documented US smoking patterns 11 to impute ages of starting and quitting (for former smokers) and cigarettes smoked per day on the basis of the birth cohort and sex for each patient (Appendix and Tables I-IV in the online-only Data Supplement).
For the following analyses, we excluded patients who were <40 years of age who presented with acute chest pain syndrome, were asymptomatic, or were referred for research purposes. In addition, we excluded patients with PNs that had previously been identified or that had demonstrated clearly benign features (diffuse, central, popcorn, or lamellated calcification; internal fat), 12 as well as patients in whom PNs were detected but no follow-up was recommended.
Cardiac CT Protocol
In all patients, a standard departmental cardiac CT protocol with the following specifications was performed: prospective or retrospective ECG synchronization, reconstruction of full field of view of 35 cm covering the entire thorax, including the chest wall in the x-y axis, and a z-axis coverage of 12 to 15 cm from the dome of the diaphragm to the carina at a 2.5-mm slice thickness without overlap. The imaging volume represented ≈70% of the lung volume.
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Lung Cancer Policy Model
To determine resource use, costs, mortality, and cost-effectiveness of a strategy to assess and to follow up PNs incidentally detected on CCTA compared with no follow-up, we used the Massachusetts General Hospital Lung Cancer Policy Model (LCPM).
14 This is a validated microsimulation model that projects the development and progression of lung cancer and the likelihood of detection, further diagnostic testing, and treatment. Individual patients are simulated until they die of lung cancer, CAD, or other causes. The model has been used to evaluate tobacco control programs and lung cancer screening programs, as well as treatments for lung cancer. [15] [16] [17] Recent comparative analyses between the LCPM and other lung cancer models in the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network demonstrated robustness and excellent consistency of the ranking of various lung cancer control scenarios. [18] [19] [20] The LCPM accommodates individual age-specific probabilities for the progression or regression of solid benign PNs and a set of risk functions for the development, distribution, and frequency of major histological types of lung cancer (adenocarcinoma, large cell, squamous cell, small cell, and non-small cell lung cancer not otherwise specified). Thus, the model reflects the heterogeneity of lung cancer with respect to growth, prognosis, and choice of treatment. If a patient is diagnosed with lung cancer in the model, treatment is assigned on the basis of the cancer type and the stage at diagnosis (ie, non-small cell lung cancer/small cell lung cancer) according to consensus guidelines. The efficacy and cost of treatment for lung cancer take into account the type and stage and are described in detail elsewhere. 14 The CAD mortality rate in the model accounted for the CAD prevalence observed in the CCTA cohort and applied the increased mortality hazards compared with no CAD estimated in the Coronary CT Angiography Evaluation For Clinical Outcomes (CONFIRM) registry (1-vessel disease, 1.79; 2-vessel disease, 2.54; 3-vessel/left main disease, 7.51).
Assumptions about downstream testing were based on Fleischner Society guidelines. 21 The accuracy of CT for the detection of PNs, conditional on nodule size and location, was based on data from the Mayo Clinic CT study. 22 A sensitivity of CT to detect a peripheral nodule of 77% was assumed for a 4-mm-diameter nodule and 100% was assumed for an 8-mm-diameter nodule. The sensitivity for central nodules was 75% of the size-specific sensitivity for a peripheral nodule. The specificity of helical CT for PNs was 0.9966, and the specificity of a diagnostic (follow-up) CT was 1.0.
Health-Related Quality of Life and Healthcare Costs
Costs of diagnostic tests and lung cancer treatment were derived from Medicare reimbursement rates and medication price lists for 2006, 15 as well as from detailed costing for different lung cancer stages. 23 We considered a societal perspective and included all relevant direct medical costs in both arms that patients incurred over their lifetime, including additional imaging studies that were not related to the actual follow-up strategy. 24 Frequencies were derived from US claims data. 25 Utility weights for quantifying health-related quality of life were derived from literature sources (Appendix and Table V in the online-only Data Supplement) and varied by age, sex, and, for lung cancer patients, cell type, stage, and treatment. Patients' concerns about the presence of a PN and its potential impact on quality of life were not included in the model.
Base-Case and Sensitivity Analyses
We used the demographic and risk factor data of each individual patient as observed in our clinical referral population (age, sex, smoking history, CAD prevalence) to create a hypothetical cohort with known disease status. This was then used to populate the LCPM to determine lung nodule follow-up per Fleischner guidelines (smoking history, size of the largest nodule) and to prognosticate cardiovascular events (CAD presence and extent as derived from CCTA prevalence). In the model, each person begins the simulation at 20 years of age and is assumed to be free of lung cancer at that time. Therefore, a patient who undergoes a CCTA at 50 years of age, for instance, is "reset" to 20 years of age when he or she enters the model. During the 30 years until the patient receives a cardiac CTA, the development of PNs is simulated in monthly cycles as a function of individual risk factors, and smoking exposure is accumulated according to the known smoking history at 50 years of age. Lung nodules can develop, grow, or (for benign nodules) regress. Thus, the true nodule characteristics (size, growth rate, location in the lung, histology, and status of distant metastases) are known in the model when the patient reaches the age at which the CCTA is conducted and the nodule is detected. Table 1 provides a validation of that assumption, namely that the hypothetical population very closely resembles the observed characteristics. The model was then used to project the short-and long-term health and economic outcomes for the cohort of patients with PNs on the CCTA study based on 2 management strategies (Figure 1) .
In strategy 1, all incidentally detected PNs were reported to referring physicians, and follow-up and downstream testing were by guest on April 29, 2017 http://circ.ahajournals.org/ Downloaded from performed according to Fleischner Society guidelines (Figure 2A and 2B). 21 In strategy 2, PNs detected during CCTA were not followed up. Detection rates, the use of tests, life expectancy, and the costs for both strategies were calculated and used to estimate the incremental effectiveness, costs, and cost-effectiveness of lung nodule follow-up. We estimated changes in lung cancer-specific and allcause mortality (3-year, 10-year, and lifetime horizons); values used to estimate incremental cost-effectiveness ratios were discounted at 3% annually.
In sensitivity analyses, we assessed the effect of restricting the population eligible for follow-up to current and previous smokers, as well as the effect of varying the time horizon of the analysis (3 years, 10 years, and lifetime).
Statistical Analysis
All comparisons are reported without P values because all analyses were run with sample sizes (275 000) large enough to generate stable estimates of the effect sizes of interest. We determined the runs per trial by first fixing the seed to ensure an identical population in the 2 arms to reduce stochastic noise. We then ran various sets of sample sizes. For each set, we estimated the average differences and standard error of the mean for quality-adjusted life-years (QALYs) and costs between the 2 strategies. We then chose the fewest number of trials to ensure that the difference in QALYs and costs between the 2 interventions was >2 times the (larger) standard error of the mean. 26 We used bootstrapping (10 000 runs with replacement of each complete data set) to derive confidence intervals for the incremental cost-effectiveness ratios.
Results
Characteristics of CCTA Referral Population and Modeled Population
Overall, 3665 patients were referred to the Massachusetts General Hospital for a clinical (ie, nonresearch) CCTA between 2005 and 2008. Among those, 591 (16%) had a PN that prompted follow-up evaluation. This cohort with PNs had a mean age of 58.7±10.2 years; 66% were men; 28% were current and 39% were former smokers; and 21% had obstructive CAD (>50% luminal narrowing). The characteristics of this population were used to create a hypothetical cohort with similar characteristics of age, sex, CAD prevalence, and smoking status that could be used in the modeling phase of our work (Table 1) . (29) 25 (4) 134 (23) 229 (38) 34 (6) 
Model-Based Health Outcomes
Using the LCPM together with our hypothetical CCTA patients with chest pain symptoms and PNs, we projected a cumulative lung cancer incidence of 0.36% (0.05% of these stage I at diagnosis) within 1 year, 0.73% (0.09% stage I) within 2 years, and 1.07% (0.14% stage I) within 3 years, with a total lifetime detection of 5.8% (0.89% stage I) in the cohort assuming no follow-up. However, overall mortality was dominated by cardiovascular disease (38%) and causes other than lung cancer and respiratory and cerebrovascular (Tables 2  and 3) .
Follow-up of PN resulted in a cumulative lung cancer incidence of 0.77% (0.37% stage I at diagnosis) within 1 year after the CCTA, 1.05% (0.46% stage I) within 2 years, and 1.20% (0.59% stage I) within 3 years, with a total lifetime detection of 5.9% (1.30% stage I; average life expectancy, 20.3 years). Hence, the relative reduction in lung cancer mortality was 8% after 3 years, 9.1% after 10 years, and 4.6% over the cohort lifetime. The cumulative lifetime lung cancer mortality was lower with follow-up compared with no follow-up (4.33% versus 4.54%, respectively). The resulting improvement in quality-adjusted life expectancy was 0.02 QALYs or 7 quality-adjusted life-days (Table 4 and 5).
Downstream Testing and Economic Outcomes
The number of CT studies within the first 3 years after reporting of the PN was 13 times higher in the follow-up group compared with the no follow-up group (follow-up, 1.77 CTs per patient versus no follow-up, 0.14 CTs per patient). In the clinical referral cohort of 591 patients, this would have corresponded to 1046 CTs with follow-up versus 83 CTs without follow-up. Combined with the increase in subsequent testing and treatment (Tables 2 and 3 ), the downstream costs were projected to be 2.8 times higher in a follow-up strategy compared with no follow-up in the first 3 years after the initial CCTA (follow-up, $1992 per person versus no follow-up, $732 per person). Over a lifetime time horizon, downstream costs in the follow-up group were $2200 per person higher than in the no follow-up group, translating into a (discounted) incremental cost-effectiveness ratio of $154 700 per QALY gained (Tables 4 and 5 ).
Follow-Up in Active Smokers Only
Although smokers had a higher cumulative lung cancer mortality (6.36% with no follow-up compared with 4.54% when nonsmokers were included), the follow-up of PNs was similarly effective in reducing lifetime mortality from lung cancer in smokers (relative mortality reduction through follow-up of PNs in the both cohorts, 4.8%). In smokers, the increase in lifetime costs with follow-up was higher per person (an additional undiscounted $745), but smokers benefitted from a larger gain in quality-adjusted life expectancy (an additional 4 undiscounted days; Tables 4 and 5), resulting in a lower (discounted) incremental cost-effectiveness ratio of $129 800 per QALY.
Discussion
Our data suggest that guideline-based follow-up of PNs incidentally detected during CCTA for chest pain evaluation results in a small relative reduction in mortality from lung cancer (8% at 3 years) and a small gain in quality-adjusted life expectancy (16.49 versus 16.47 years) compared with a strategy of no follow-up. This gain is achieved at the cost of a substantial increase in downstream testing, staging, and treatment that results in additional lifetime costs of $2200 per person compared with no follow-up and translates into costs of $154 700 per QALY gained. Follow-up strategy is Notably, our model predicted a smaller relative reduction in lung cancer mortality at 10 years than the National Lung Screening Trial (NLST) reported at 7 years (9% versus 20%). 27 However, this is consistent with the fact that our population was not selected on the basis of heavy smoking history and that we considered only 1 examination (ie, in which the nodule was found) rather than 3 consecutive screening examinations as preformed in the NLST.
The strengths of our analysis are (1) the use of original data to inform the model; (2) the use of a validated and established lung cancer model simulating the natural history of detected PNs and lung cancer and the associated diagnostic testing, treatment, and mortality; and (3) consideration in the model of competing mortality from CAD and other causes over different time horizons.
Although there is no mandate in US health policy to consider a certain cost-effectiveness threshold for approval or payment of medical interventions, an often-cited threshold is US $100 000 per QALY. [28] [29] [30] Compared with other interventions (eg, CAD screening in patients with type 2 diabetes mellitus 31 or CAD screening in HIV patients), 32 follow-up of PN incidentally detected during CCTA evaluation for chest pain appears to be cost-inefficient, especially in nonsmokers.
It is further important to emphasize that the present study does not investigate the clinical validity or the appropriateness of the Fleischner Society guidelines but rather may inform clinical practice by providing information about the benefits and costs to society. Future analyses should include comparative analyses between different lung cancer models to assess the impact of follow-up of nodules incidentally detected during CCTA, to further assess the robustness of the results, and CAD indicates coronary artery disease; CT, computed tomography; CXR, chest x-ray; LCPM, lung cancer policy model; PET, positron emission tomography; PN, pulmonary nodule; and VATS, video-assisted thoracic surgery.
*Includes costs for CXR, CT, and PET. †Includes costs for bronchoscopies, mediastinoscopies, VATS, transthoracic needle aspiration, and PET for staging. ‡Includes costs for surgery, chemotherapy, radiotherapy, best supportive care, and CT for surveillance. Undiscounted costs are shown for all cost categories and time points.
by guest on April 29, 2017 http://circ.ahajournals.org/ Downloaded from to determine future research priorities. These analyses should also investigate different subgroups and assess to what extent the Fleischner guidelines are applicable to a primarily cardiac population.
There are several limitations to this study. First, the results are based on a simulation using the characteristics of a clinical cohort at a single referral center who were referred for CCTA. However, the validity of our analysis is supported by the fact that our model predicted all-cause mortality rates that approximate those observed in similar registry patients. For example, the predicted annual all-cause mortality of 1.32% in our cohort was comparable to the observed all-cause mortality rate of 0.93% in the CONFIRM registry 2 even though our cohort was on average 3 years older (58 versus 61 years) and had a greater proportion of male patients (60% versus 65%). In addition, it was similar to that of the NLST with an annual all-cause mortality of 1.15%. 27 Furthermore, the frequency and location of incidentally detected PNs in our study were based on a field of view that covered only 70% of the total lung. 12 However, the projected rate of 16% of PNs requiring follow-up in our population was similar to those in previous observational studies, 6, 7 and the demographics of our clinical referral population, including the prevalence of obstructive CAD, were similar to those of the CONFIRM registry.
2 From these findings, we believe that our data should be generalizable to a typical CCTA referral population with stable chest pain syndromes. Furthermore, the LCPM is a well-validated simulation model that uses established risk factors (age, sex, smoking history) to simulate the development of benign and malignant nodules; however, the present version does not yet incorporate different nodule features such as attenuation (ground glass, mixed, or solid). Lung cancers that present as ground-glass nodules have been associated with a better prognosis, 33, 34 leading radiologists to recommend different lengths and frequencies of imaging follow-up for these nodules compared with solid nodules. 35, 36 In addition, the simulation model does not take into account the location of the PNs; however, perifissural nodules are now considered to have low malignancy potential. 37 Finally, we assumed complete adherence of follow-up according to Fleischner Society guidelines, although actual clinical practice and downstream testing and costs may vary.
Conclusion
Routine follow-up of incidentally detected PNs in stable symptomatic patients undergoing CCTA resulted in a small reduction in lung cancer mortality at the cost of significant downstream testing, leading to a high cost per QALY, especially in nonsmokers.
CLINICAL PERSPECTIvE
This study provides the first estimation of both the costs and health benefits associated with follow-up of pulmonary nodules incidentally detected during cardiac computed tomographic angiography. The analyses suggest a small relative reduction in lung cancer mortality of 8% at 3 years. However, given that the absolute lung cancer mortality rate in the population is <5% compared with ≈38% for cardiovascular disease mortality and 57% for other causes, the absolute gain from follow-up of lung nodules was 7 quality-adjusted life-days. This gain is achieved at the cost of a substantial increase in downstream testing, staging, and treatment that results in additional lifetime costs of $2200 per person compared with no follow-up, resulting in an additional $154 700 per quality-adjusted life-year gained. Results looked slightly more favorable when the follow-up was restricted to smokers, yielding additional costs of $129 800 per quality-adjusted life-year gained. Compared with other interventions (eg, coronary artery disease screening in patients with type 2 diabetes mellitus or coronary artery disease screening in HIV patients), follow-up of pulmonary nodules incidentally detected during cardiac computed tomographic angiography evaluation for chest pain appears to be cost-inefficient, especially in nonsmokers. Although there currently is no mandate in the United States to take into account certain cost-effectiveness thresholds in making health policies, this is 1 of several important considerations that clinicians who refer to and interpret cardiac computed tomographic will need to keep in mind in the context of increasingly scarce resources. 
Smoking imputation
The MGH Lung Cancer Policy Model requires a detailed smoking history to simulate development of pulmonary nodules and lung cancer, including ages of smoking initiation and cessation (for former smokers) and cigarettes smoked per day which were not available to us from the medical records. Benefitting from direct access to the work by Anderson and colleagues who documented US smoking patterns 1 , we imputed the missing values for each patient in our CCTA cohort, using the following three step approach
Step 1: Age of initiation was imputed by drawing from the distribution of the natural logarithm for the respective birth cohort and gender of the individual patients (table 1) . We chose the natural logarithm of the age instead of the actual value because this better approximated a normal distribution. This value was then transformed back using exp(x) for the subsequent steps to derive a value in years which is referred to as starting_age in the subsequent steps.
Supplemental material, page 2 Step 2: Cigarettes per day (CPD) for the individual patients in the CCTA cohort were imputed using the starting age as determined in step 1 and regression coefficients as displayed table 2 for respective birth cohort and gender.
We used the following formula:
This value is reported in number (n) of cigarettes per day, and will be referred to as CPD in the subsequent step.
Supplemental material, page 3 Step 3: Finally, age of smoking cessation for former smokers was imputed as a function of the individual patient's age of smoking initiation (from step 1) and cigarettes consumed per day (from step 2) and the interaction term between age of smoking initiation and CPD (interaction), again stratified by birth cohort and gender, using regression coefficients from a linear regression analysis based on the work by Anderson and colleagues 1 (tables 3a and 3b).
Age of cessation (years) = intercept + Coef_cigs_day* cpd (in N) + Coef2_age_start * starting_age (in years) + interaction *CPD (in N)* starting_age (in years)
Supplemental material, page 4 Supplemental material, page 6
Utility
The following utility weights were applied to the model for non-lung cancer patients The following utility weights were applied to the model for lung cancer patients. 
